Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
7.3
46.24%
80%
—
11x
Every year
—
5 Years
Score7.3
Net Growth46.24%
Net Trend80%
Net Income Consistency—
Rev Growth11x
Rev TrendEvery year
Revenue Consistency—
Hyperfine Inc fundamental performance
Between 2021 and 2025, revenue grew from $ 1M to $ 13M and net income went from -$ 64M to -$ 35M. Revenue increased in 100% of the years measured; net income in 80%.
Hyperfine Inc currently holds a 5-year HDB Score of 7.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-13 | $ 0.89 | — |
1 Year2025-08-13 | $ 1.27 | -29.66% |
5 Years2021-08-13 | $ 9.94 | -91.01% |
All Time2021-01-27 | $ 10.01 | -91.08% |
| Period | Last Price2026-08-13 | 1 Year2025-08-13 | 5 Years2021-08-13 | All Time2021-01-27 |
|---|---|---|---|---|
| Price | $ 0.89 | $ 1.27 | $ 9.94 | $ 10.01 |
| Return | — | -29.66% | -91.01% | -91.08% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 16M | -$ 34M | $ 43M |
| 2025 | $ 13M | -$ 35M | $ 35M |
| 2024 | $ 12M | -$ 40M | $ 37M |
| 2023 | $ 11M | -$ 44M | $ 75M |
| 2022 | $ 6M | -$ 73M | $ 118M |
| IPO2021 | $ 1M | -$ 64M | $ 188M |
Explore beyond HYPR
You're looking at Hyperfine Inc. Members apply the same fundamental framework across all 3,859 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,859 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
Explore other companies
- Healthcare Services Group IncHCSG· revenue grew in 80% of years
- Protagonist Therapeutics IncPTGX· revenue grew in 60% of years
- Tactile Systems Technology IncTCMD· revenue grew in 100% of years
- Amneal Pharmaceuticals, Inc. Class A Common StockAMRX· revenue grew in 100% of years
- Incyte CorporationINCY· revenue grew in 100% of years
